Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/52637
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampClaudino, Mário Angelopt_BR
dc.contributor.authorunicampSilva, Fábio Henrique dapt_BR
dc.contributor.authorunicampDe Nucci, Gilbertopt_BR
dc.contributor.authorunicampMónica, Fabíola Zakia Tauficpt_BR
dc.contributor.authorunicampRojas Moscoso, Julio Alejandropt_BR
dc.contributor.authorunicampAntunes, Edsonpt_BR
dc.typeArtigopt_BR
dc.titleLong-term oral treatment with BAY 41-2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat modelpt_BR
dc.contributor.authorClaudino, M.A.pt_BR
dc.contributor.authorSilva, F.H. dapt_BR
dc.contributor.authorDe Nucci, G.pt_BR
dc.contributor.authorMonica, F.Z.T.pt_BR
dc.contributor.authorRojas-Moscoso, J.A.pt_BR
dc.contributor.authorAntunes, E.pt_BR
dc.subjectDisfunção erétilpt_BR
dc.subject.otherlanguageErectile dysfunctionpt_BR
dc.description.abstractTo investigate the potential beneficial effects of 4-week oral treatment with 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1Hpyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine (BAY 41-2272), a nitric oxide (NO)independent soluble guanylate cyclase activator, on impaired rat corpus cavernosum relaxations in NO-deficient rats. MATERIAL AND METHODS Male Wistar rats were divided into four groups: Control, N (G)-nitro-L-arginine methyl ester (L-NAME; 20 mg/rat/day), BAY 41-2272 (20 mg/kg/day) and L-NAME + BAY 41-2272. Rats were treated with L-NAME concomitantly with BAY 41-2272 for 4 weeks. Concentration-response curves to acetylcholine (ACh) and sodium nitroprusside (SNP), along with the nitrergic relaxations (1-32 Hz) were obtained in rat corpus cavernosum (RaCC). The RaCC contractile responses to the alpha(1)-adrenoceptor agonist phenylephrine (PE) were obtained. RESULTS Acetylcholine (0.01-1000 mu mol/L) produced concentration-dependent relaxing responses in RaCC that were significantly enhanced (P < 0.05) in BAY 41-2272-treated rats. The ACh-induced relaxations were largely reduced in L-NAME-treated rats, and co-treatment with BAY 41-2272 failed to significantly modify these impaired relaxations. The SNP-induced relaxations were modified neither by L-NAME nor by co-treatment with BAY 41-2272. The nitrergic relaxations were significantly amplified in BAY 41-2272-treated rats (at 16 and 32 Hz). A significant reduction in the nitrergic relaxations was observed in L-NAME-treated rats, an effect largely restored by co-treatment with BAY 41-2272. The contractile RaCC responses produced by PE (0.001-100 mu mol/L) were significantly higher (P < 0.05) in L-NAME-treated rats, and co-treatment of L-NAME with BAY 41-2272 nearly restored these enhanced contractile responses. CONCLUSION Four-week therapy with BAY 41-2272 prevents the impaired corpus cavernosum relaxations of rats treated chronically with L-NAME, indicating that accumulation of cyclic guanosine monophosphate into erectile tissue counteracts the NO deficiencypt
dc.relation.ispartofBJU Internationalpt_BR
dc.relation.ispartofabbreviationBJU int.pt_BR
dc.publisher.cityChichesterpt_BR
dc.publisher.countryReino Unidopt_BR
dc.publisherWileypt_BR
dc.date.issued2011pt_BR
dc.date.monthofcirculationJulypt_BR
dc.identifier.citationBju International. Wiley-blackwell, v. 108, n. 1, n. 116, n. 122, 2011.pt_BR
dc.language.isoengpt_BR
dc.description.volume108pt_BR
dc.description.issuenumber1pt_BR
dc.description.firstpage116pt_BR
dc.description.lastpage122pt_BR
dc.rightsfechadopt_BR
dc.sourceWeb of Sciencept_BR
dc.identifier.issn1464-4096pt_BR
dc.identifier.eissn1464-410Xpt_BR
dc.identifier.doi10.1111/j.1464-410X.2010.09776.xpt_BR
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/full/10.1111/j.1464-410X.2010.09776.xpt_BR
dc.description.sponsorshipFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPpt_BR
dc.description.sponsorship1FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOpt_BR
dc.description.sponsordocumentnumbersem informaçãopt_BR
dc.date.available2014-07-30T13:38:53Z
dc.date.available2015-11-26T16:29:39Z-
dc.date.accessioned2014-07-30T13:38:53Z
dc.date.accessioned2015-11-26T16:29:39Z-
dc.description.provenanceMade available in DSpace on 2014-07-30T13:38:53Z (GMT). No. of bitstreams: 0 Previous issue date: 2011 Bitstreams deleted on 2020-05-18T20:40:56Z: WOS000291928500025.pdf,. Added 1 bitstream(s) on 2020-05-19T14:30:40Z : No. of bitstreams: 2 000291928500025.pdf: 576984 bytes, checksum: dfc5aa2f15ee9e29250c7671d8e07248 (MD5) WOS000291928500025.pdf.txt: 37906 bytes, checksum: dcd25a0847180fc3a9dd63f23181c5c7 (MD5)en
dc.description.provenanceMade available in DSpace on 2015-11-26T16:29:39Z (GMT). No. of bitstreams: 2 WOS000291928500025.pdf: 501319 bytes, checksum: 8641eeb9bda9872dcd20c9c4d410a4e3 (MD5) WOS000291928500025.pdf.txt: 37906 bytes, checksum: dcd25a0847180fc3a9dd63f23181c5c7 (MD5) Previous issue date: 2011en
dc.identifier.urihttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/52637
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/52637-
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.identifier.source000291928500025-
dc.creator.orcid0000-0002-3590-9607pt_BR
dc.creator.orcidsem informaçãopt_BR
dc.creator.orcid0000-0002-4346-7941pt_BR
dc.creator.orcid0000-0002-8449-6677pt_BR
dc.creator.orcidsem informaçãopt_BR
dc.creator.orcid0000-0003-2201-8247pt_BR
dc.type.formArtigo originalpt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000291928500025.pdf563.46 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.